Radiotherapy after breast-conservation surgery: how much is enough?
The National Surgical Adjuvant Breast Project (NSABP) clinical trials have demonstrated that breast conservation surgery (lumpectomy), axillary dissection, and breast irradiation for women with Stage I and II invasive breast carcinoma provide disease-free survival and overall survival rates equivalent to modified radical mastectomy. Breast irradiation following lumpectomy decreases the incidence of in-breast tumor recurrence compared to lumpectomy alone. The addition of adjuvant systemic therapy appears to further decrease the incidence of in-breast tumor recurrence. Irradiation of the internal mammary and supraclavicular nodal regions is not indicated for patients with Stage I and II carcinoma. Similarly, irradiation of the axilla after axillary dissection is not indicated.
Deutsch
M
M
Department of Radiation Oncology, University of Pittsburgh Health Center, Pennsylvania.
D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002985:Clinical Protocols / Q000592:standards; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003663:Decision Trees; D005260:Female; D006801:Humans; D015994:Incidence; D008197:Lymph Node Excision / Q000592:standards; D015409:Mastectomy, Radical / Q000592:standards; D015412:Mastectomy, Segmental / Q000592:standards*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000592:standards*; D011879:Radiotherapy Dosage; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone